利妥昔单抗与环磷酰胺治疗膜性肾病的RI-CYCLO随机试验
该试验将74例蛋白尿>3.5 g/d的膜性肾病患者随机分配至利妥昔单抗组或环磷酰胺交替激素的6个月周期方案组。12个月完全缓解率利妥昔单抗组为16%、周期方案组为32%(OR 0.4, 95%CI 0.13-1.23),24个月完全或部分缓解概率两组相近,严重不良事件发生率分别为19%和14%。
要点
- 利妥昔单抗与环磷酰胺周期方案在12个月完全缓解率无显著差异
- 24个月完全或部分缓解概率两组接近(利妥昔单抗0.83 vs 周期方案0.82)
- 严重不良事件发生率利妥昔单抗19%、环磷酰胺周期方案14%
核心结论
- 该预试验未发现利妥昔单抗相比环磷酰胺交替激素周期方案在膜性肾病治疗中更多获益或更少 harm 的信号。
研究设计与样本
- 随机对照预试验,纳入74例蛋白尿>3.5 g/d的成人膜性肾病患者,随机分配至利妥昔单抗组(第1、15天各1 g)或6个月环磷酰胺交替激素周期方案组。
主要发现
- 12个月完全缓解:利妥昔单抗组6/37(16%),周期方案组12/37(32%),OR 0.4(95%CI 0.13-1.23)。
- 12个月完全或部分缓解:利妥昔单抗组23/37(62%),周期方案组27/37(73%),OR 0.61(95%CI 0.23-1.63)。
- 24个月完全缓解概率:利妥昔单抗0.42(95%CI 0.26-0.62),周期方案0.43(95%CI 0.28-0.61)。
- 24个月完全或部分缓解概率:利妥昔单抗0.83(95%CI 0.65-0.95),周期方案0.82(95%CI 0.68-0.93)。
- 严重不良事件:利妥昔单抗组19%,周期方案组14%。
临床怎么用
- 对于蛋白尿>3.5 g/d的膜性肾病患者,利妥昔单抗可作为环磷酰胺周期方案的替代选择,但需结合安全性和患者具体情况个体化决策。
局限性
- 该研究为预试验,样本量小(74例),主要终点置信区间宽,需全球非劣效性试验进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking. METHODS: We randomly assigned 74 adults with membranous nephropathy and proteinuria >3.5 g/d to rituximab (1 g) on days 1 and 15, or a 6-month cyclic regimen with corticosteroids alternated with cyclophosphamide every other month. The primary outcome was complete remission of proteinuria at 12 months. Other outcomes included determination of complete or partial remission at 24 months and occurrence of adverse events. RESULTS: At 12 months, six of 37 patients (16%) randomized to rituximab and 12 of 37 patients (32%) randomized to the cyclic regimen experienced complete remission (odds ratio [OR], 0.4; 95% CI, 0.13 to 1.23); 23 of 37 (62%) receiving rituximab and 27 of 37 (73%) receiving the cyclic regimen had complete or partial remission (OR, 0.61; 95% CI, 0.23 to 1.63). At 24 months, the probabilities of complete and of complete or partial remission with rituximab were 0.42 (95% CI, 0.26 to 0.62) and 0.83 (95% CI, 0.65 to 0.95), respectively, and 0.43 (95% CI, 0.28 to 0.61) and 0.82 (95% CI, 0.68 to 0.93), respectively, with the cyclic regimen. Serious adverse events occurred in 19% of patients receiving rituximab and in 14% receiving the cyclic regimen. CONCLUSIONS: This pilot trial found no signal of more benefit or less harm associated with rituximab versus a cyclic corticosteroid-cyclophosphamide regimen in the treatment of membranous nephropathy. A head-to-head, pragmatic comparison of the cyclic regimen versus rituximab may require a global noninferiority trial. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Rituximab versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO), NCT03018535.
引用
- Scolari F, Delbarba E, Santoro D, et al. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021. PMID: 33649098. doi:10.1681/ASN.2020071091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。